1507results about "Peptide-nucleic acids" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

The invention belongs to the technical field of genetic engineering, and particularly relates to an antibacterial peptide with antibacterial and antiviral effects and application and a product thereof. The amino acid sequence of the antibacterial peptide provided by the invention has the following general formula: X1GX2FX3FX4KKFX5LFX6X7SKVLK, x1 is M or has no amino acid; x2 is one of R, G and H; x3 is one of KS, KR, HR and HH; x4 is R or L; x5 is one of KK, HH and HK; x6 is RR or KK; and X7 is I or L. The antibacterial peptide disclosed by the invention has a relatively good antibacterial effect, and shows antiviral activity on HPV16 (Human Papilloma Virus 16) and HPV18 (Human Papilloma Virus 18). Good application prospects are shown in the preparation of antibacterial or antiviral products.

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

The invention discloses a polypeptide derivative with a GCGR, GIPR and GLP-1R triple targeting agonistic effect as well as a preparation method and application of the polypeptide derivative, the polypeptide derivative is shown as a formula (I), (II) is a branched chain modification structure of a peptide chain, and the group definition is detailed in the specification. The polypeptide derivative compound and the pharmaceutically acceptable salt thereof provided by the invention can be used for treating metabolic related diseases such as diabetes mellitus, weight loss, MASH and the like, cardiovascular and cerebrovascular diseases and / or neurodegenerative diseases. Tyr-Aib-Gln-Gly-Thr-Ph-Thr-Ser-Asp-Tyr-Ser-Xaa12-Xaa13-Leu-As-Lys-Xaa17-Ala-Gln-Xaa24-Xaa25-Leu-Leu-Xaa28-Gly-Ala-Pro-Pro-Ser-NH2 (I) # imgabs0 #

The invention is applicable to the technical field of polypeptides, and provides a novel antibacterial peptide GG25 and application thereof, and the amino acid sequence of the antibacterial peptide GG25 is as shown in SEQ ID No.1. The molecular weight of the novel antibacterial peptide GG25 is 2890.52 Da, and the novel antibacterial peptide GG25 has antibacterial activity on escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, enterococcus faecalis, salmonella typhimurium, methicillin-resistant staphylococcus aureus, staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes and bacillus subtilis; the hemolytic activity is low, the cytotoxicity is small, and the escherichia coli and methicillin-resistant staphylococcus aureus are not easily induced to generate drug resistance; in addition, the gelatin chitosan food coating containing GG25 also has a good beef preservation effect, and can be applied to the fields of food, animal husbandry, medicine and the like.

Disclosed are compounds of Formula (I): # imgabs0 # or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R3, X, Y, Z and W are as defined herein. The compounds are inhibitors of, for example, WRN helicase and are useful in the treatment of proliferative diseases such as cancer.

The present invention relates to the field of microbial self-assembling protein fibrils as novel bionanomaterials. More specifically, the present invention relates to protein nanofibril materials comprising Bacillus endospore appendage (ENA) proteins, which are spontaneously folding helix hairpin subunits assembling into alpha-helical multimeric (A-ENA) fibrils with a hydrophobic core and covalently connected by one or more isopeptidic bonds, providing for a nanofibril of high stability and tensile strength. The invention further relates to said protein nanofibrils which are engineered or modified to provide for functionalized bionanomaterials. In particular, the invention relates to methods for recombinant production of said self-assembling protein nanofibrils, and their use in modifying bacterial endospores and endospore activity or pathogenicity.

The invention provides a synthetic anti-cancer lipopeptide and application thereof, and particularly provides a non-natural polypeptide comprising domains X1, X2 and X3, in which X1 is selected from C6-C20 fatty acid residues, X2 is selected from C6-C20 fatty acid residues, X3 is selected from C6-C20 fatty acid residues, and X3 is selected from C6-C20 fatty acid residues; x2 is selected from a fragment of a cell penetrating peptide (CPPs); x3 is selected from fragments of peptides that specifically bind to protein kinase 2 (CK2). Compared with the prior art, the polypeptide can more effectively inhibit CK2, has higher targeting property on RPS6 protein, has better tumor inhibition activity and anti-metastasis effect and higher safety, and can realize large-scale production.

The invention belongs to the technical field of biological medicines, and particularly relates to a pleiotropic protein MEL3 and application thereof. The amino acid sequence of the pleiotropic protein MEL3 or the homologous protein of the pleiotropic protein MEL3 provided by the invention has the following general formula: X1GAX2LX3VLX4GLX5ALISWEKRKRX6, x1 is M or L; the X2 is one of V, SI and AI; x3 is one of K, T, KI and KR; x4 is one of KK, TT, SS and VK; x5 is one of P, K, A and T; and X6 is QQ or is free of amino acid. The pleiotropic protein MEL3 or the homologous protein thereof provided by the invention has broad-spectrum antibacterial activity, can achieve anti-inflammatory and antiviral effects at the same time, and provides a new thought for preparing anti-pathogenic microorganism or anti-inflammatory products.

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The invention relates to an anti-RSV polypeptide membrane fusion inhibitor as well as a preparation method and application thereof. The invention discloses a compound, a pharmaceutical salt or a derivative thereof, a pharmaceutical composition and a preparation product containing the compound, and application of the compound and the pharmaceutical salt or the derivative in preparation of medicines for preventing and / or treating diseases caused by RSV or other paramyxoviridae viruses. The polypeptide disclosed by the invention shows the anti-RSV activity and safety which are obviously superior to those of positive control polypeptide. Molecular interaction experiments show that the polypeptide acts on the NHR region of the RSV F protein, and the fusion of the RSV virus and a target cell is prevented by forming an inactive six-helix structure with NHR, or by destroying the RSV NHR structure and inhibiting the process of forming a six-helix bundle by NHR and CHR in the F protein in the key step of RSV infection.

A nutritional polypeptide having branched-structure with efficient broad-spectrum antibacterial and antifungal functions provided. The nutritional polypeptide having branched-structure is a polypeptide containing L-lysine or D-lysine moieties having a molecular weight of 3000-7000 Da. The branched-structured polypeptide has a highly efficient broad-spectrum antibacterial effect against bacteria, fungi and mycoplasma at low concentrations without developing resistance. Compared with conventional antimicrobials, the disclosed polypeptides have excellent biocompatibility, are non-cytotoxic, have no adverse effects on animals by intravenous injection, and can satisfy the requirements of intravenous antimicrobials in vivo. The degradation product is lysine, a nutrient essential to the organism, which has no toxic side effects. The branched-structured polypeptide is chemically synthesized throughout without the need of biofermentation processes, and is physically, chemically and biologically stable. It can be physically or chemically combined with other materials, synthesized or processed into various forms of materials and retain efficient antimicrobial properties.

The invention belongs to the technical field of preparation of polypeptides, and particularly relates to a self-assembled polypeptide capable of responding to alkaline phosphatase and degrading Neuropilin-1 as well as a preparation method and application of the self-assembled polypeptide. The self-assembled polypeptide (formula I) provided by the invention has a self-assembly starting unit 'GNNQQNY (SEQ ID NO: 1)', can be self-assembled in vitro, and can form nanofibers after responding to alkaline phosphatase, so that not only can the critical self-assembly concentration of the polypeptide be reduced, but also the binding capacity with target protein can be improved. The material can degrade NRP1 on the surfaces of tumor cells and Treg cells, and has huge potential in promoting immunotherapy of tumors.

This invention belongs to the field of biomedical technology and discloses a method for targeting GABA. A The receptor-dependent cyclic peptide analgesic DZ2 has the following amino acid sequence: Cys-Asn-Thr-Glu-Arg-Pro-Gly-Met-Leu-Asp-Phe-Lys-Gly-Lys-Ala-Lys-Trp-Asp-Ala-Trp-Cys, where the N-terminal Cys and C-terminal Cys are cyclically linked by a disulfide bond, and the molecular weight is 2454.81 g / mol. This cyclic peptide can be obtained through classic Fmoc-solid-phase synthesis, using GABA... A Receptor-targeting drugs play an important role in drug development. The compounds provided in this invention can activate GABA. A The receptor generates a GABA-like inward current. Furthermore, DZ2 exhibits excellent analgesic effects in a mouse pain model, providing a potential alternative for GABA-based analgesics. A This provides new ideas and theoretical basis for the development of receptor-based analgesics.

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The present disclosure comprises hydrophilic linker compounds of Formula 1:and describes methods for their use in liquid phase synthesis. In Formula 1, “m” is 0 to 20, “n” is 1 to 50, and “Z” is a linker compound as described herein.

The invention provides a polypeptide composition and application thereof in treating male erectile dysfunction. Specifically, the polypeptide composition contains the erectile peptide screened and identified by the invention, and the erectile peptide has good oxidation fatigue resistance, can effectively promote penile erection, improve testosterone level and effectively treat erectile dysfunction, and has wide application prospects.

The invention discloses a radionuclide-labeled collagen hybrid peptide probe as well as a preparation method and application thereof. The chemical structural general formula of the radionuclide-labeled collagen hybrid peptide probe is (metal nuclide-chelating agent)-Linker-CHP, wherein the metal nuclide is selected from any one of Al18F, 64Cu, 67Cu, 67Ga, 68Ga, 99mTc, 89Zr, 111In, 177Lu, 186Re and 225Ac, and the metal nuclide is selected from any one of Al18F, 64Cu, 67Cu, 67Ga, 68Ga, 99mTc, 89Zr, 111In, the chelating agent is selected from any one of NODAGA, NOTA2 and DOTA; linker is a connecting joint, and CHP is a collagen hybrid peptide with a polypeptide sequence of (GfO) n or (GPO) n. The probe not only has the characteristic of radiochemical marking stability, but also has the excellent biological distribution characteristics of high uptake in target organs such as tumors and low uptake in non-target organs such as liver and kidney, and has a good clinical application prospect.

The invention provides a multifunctional protein MZM29 and application thereof, and belongs to the technical field of biological medicine. The multifunctional protein MZM29 or the homologous multifunctional protein of the MZM29 provided by the invention comprises an amino acid sequence as shown in any one of SEQ ID NO.1-12; or a partial segment comprising any one or more of the amino acid sequences shown as SEQ ID NO.1-12, or a partial segment comprising any one or more of the amino acid sequences shown as SEQ ID NO.1-12; or a sequence having more than 80% of homology with any one amino acid sequence of SEQ ID NO.1-12. The multifunctional protein MZM29 has relatively good antibacterial and anti-inflammatory effects, and shows antiviral activity to HPV16 and HPV18. Good application prospects are shown in preparation of antibacterial, anti-inflammatory or anti-virus products.

The present invention belongs to the field of biotechnology, and in particular, relates to an antimicrobial peptide derived from lactic acid bacteria and its application in the preparation of oral antibacterial products. The amino acid sequence of the antimicrobial peptide provided by the present invention is shown in SEQ ID NO. 1. The antimicrobial peptide has excellent antibacterial effect and has significant antibacterial effect on a variety of common oral pathogens such as Porphyromonas odonta, Prevotella intermedia, Streptococcus mutans, Staphylococcus aureus, etc. The antimicrobial peptide can be used as a new choice of active ingredients of antimicrobial drugs or other antimicrobial products, especially as an antimicrobial active ingredient of oral antimicrobial products, such as the antimicrobial active ingredient of anti-infection toothpaste. In addition, the present invention also provides a recombinant plasmid containing a nucleotide sequence encoding the above antimicrobial peptide and a construction method thereof, as well as a recombinant bacterium expressing the above antimicrobial peptide and a construction method thereof. By adopting a codon-optimized nucleotide sequence, the coding efficiency is improved, and high expression of the antimicrobial peptide can be achieved.

Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-haripin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.

The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.

The invention relates to a long-acting GLP-1 / GIP dual agonist compound, the compound has dual agonist effects on a glucagon-like peptide-1 (GLP-1) receptor and a human glucose-dependent insulinotropic polypeptide (GIP) receptor, and the invention also relates to application of the compound in preparation of a medicine for treating diabetes mellitus.

The present disclosure provides a novel synthetic method for preparing GLP-1R / GIPR agonists. Also provided is a synthetic method for preparing 2-((2-oxo-2-((2-(2-oxopiperidin-1-yl)ethyl)amino)ethyl)thio)acetic acid.

the present invention relates to peptides, in particular cell-penetrating peptides, having a first hydrophobic domain positioned at the C-terminus of the peptide and a second hydrophobic domain positioned at the N-terminus of the peptide, and to conjugates of such cell-penetrating peptides with a therapeutic molecule. The present invention further relates to use of such peptides or conjugates in methods of treatment or as a medicament, especially in the treatment of genetic disorders and in particular muscular dystrophies such as Duchenne muscular dystrophy.

The present invention discloses an L-shaped fiber supramolecule and its preparation method and application. The structural formula of the L-shaped fiber supramolecule is shown in formula (I). The preparation method includes: activation of resin, coupling of amino acids, excision and precipitation of polypeptides, and separation and purification of polypeptides. The L-shaped fiber supramolecule prepared by the present invention has good biocompatibility, does not cause inflammatory reaction at the wound site, has the function of binding calcium ions, and exhibits excellent effects in hemostasis and bone regeneration. #imgabs0#

Provided herein are self-assembling collagen-like peptide (CLP) comprising a plurality of amino acid trimer repeats having the amino acid sequence POG, wherein P is a proline, O is an hydroxyproline or a cysteine, and G is a glycine or a valine. Also provided herein are compositions, scaffolds, photoactivatable hydrogel precursors and hydrogels comprising the CLP and a multi-arm polyethylene glycol (PEG) polymer. Methods of preparing photoactivatable hydrogel precursors and hydrogels are also described. Methods of treating a wound, of treating a corneal disease, of treating a myocardial infarct, of promoting cell growth and of treating cellular degeneration using the compositions, scaffolds, photoactivatable hydrogel precursors and / or hydrogels are also described. Also provided is a device for delivering a peptide-based material. The device comprises an on / off button or switch for initiating and stopping delivery of the peptide-based material in the subject; a chamber for containing the peptide-based material; an aperture through which the peptide-based material exits the chamber, wherein the aperture is adapted for receiving a nozzle adapter; a camera port for securing a camera thereto; and a digital control display.

The invention belongs to the technical field of biological materials, and particularly relates to polypeptide MSE for enzyme-responsive targeted degradation of EGFR protein and anti-tumor application of the polypeptide MSE. The amino acid sequence of the polypeptide MSE is as shown in SEQ ID NO. 1. The polypeptide MSE can be combined with EGFR protein on the surface of a cell membrane in a co-localization mode, degrade the EGFR protein on the cell membrane and promote tumor cell apoptosis through an active oxygen signal channel, has an anti-tumor effect in vivo and in vitro, has good biological safety and is expected to provide a new thought for cancer treatment.

Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. The peptides include the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and / or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.